Transforming growth factor-β (TGF-β) signaling is involved in glioma development. The monoclonal antibody fresolimumab (GC1008) can neutralize all mammalian isoforms of TGF-β, and tumor uptake can be visualized and quantified with 89 Zr-fresolimumab PET in mice. The aim of this study was to investigate the fresolimumab uptake in recurrent high-grade gliomas using 
Zr-fresolimumab PET in mice. The aim of this study was to investigate the fresolimumab uptake in recurrent high-grade gliomas using 89 Zr-fresolimumab PET and to assess treatment outcome in patients with recurrent high-grade glioma treated with fresolimumab.
Patients and methods:
Patients with recurrent glioma were eligible. After intravenous administration of 37 MBq (5 mg) of 89 Zr-fresolimumab, PET scans were acquired on day 2 or day 4 after tracer injection. Thereafter, patients were treated with 5 mg of fresolimumab per kilogram intravenously every 3 weeks. 89 Zr-fresolimumab tumor uptake was quantified as maximum standardized uptake value (SUVmax). MR imaging for response evaluation was performed after 3 infusions or as clinically indicated.
Results: Twelve patients with recurrent high-grade glioma were included: 10 glioblastomas, 1 anaplastic oligodendroglioma, and 1 anaplastic astrocytoma. All patients underwent 89 Zr- 
Conclusion:
89 Zr-fresolimumab penetrated recurrent high grade gliomas very well but did not result in clinical benefit.
4

IntroductIon
High grade gliomas are rapidly progressive brain tumors that are divided into anaplastic gliomas and glioblastomas multiforme (GMB) on the basis of their histopathologic features. The 5-year survival rates for anaplastic oligodendroglioma, anaplastic astrocytoma and GBM are 49%, 25%
and 5%, respectively. 1 In addition to surgery, the standard treatment of gliomas is currently based on tumor cell death induction by radiotherapy and chemotherapy. As a result of the modest treatment results, novel strategies for the treatment of malignant glioma are needed.
Transforming growth factor-β (TGF-β) acts as a tumor promoter in advanced tumors, where it induces proliferation and metastasis and suppresses the immune response. 2 TGF-β and its receptors are overexpressed in GBM, and TGF-β signaling is involved in multiple steps of GBM development and invasion. [3] [4] [5] Plasma TGF-β levels are elevated in GBM patients and decrease after surgical tumor resection. 6 In addition, progression-free survival (PFS) and overall survival are decreased in glioma patients with high levels of phosphorylated SMAD2 (p-SMAD2), the substrate of the TGF-β receptor I, compared with glioma patients with low levels of p-SMAD2. 7 These features make TGF-β a promising target molecule for therapeutic approaches in recurrent glioma; therefore, several TGF-β-inhibitors are under investigation in this setting. Fresolimumab (GC1008) is a monoclonal antibody capable of neutralizing all mammalian isoforms of TGF-β (i.e. 1, 2, and 3). 9 In a phase 1 study with fresolimumab in patients with melanoma and renal cell carcinoma, 6 patients achieved stable disease and one patient had a partial response. 10 In a phase 2 study in 13 mesothelioma patients stable disease was seen in 3 patients at 3 months.
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Current standard-of-care and experimental treatment results in patients with recurrent highgrade glioma are disappointing. It is often suggested that this is because of the impermeability of the blood-brain barrier, which may prevent drugs from reaching the tumor. 12 For therapeutic success in brain tumors, it is essential for a monoclonal antibody such as fresolimumab to reach the target site in the brain. In tumor xenograft models, tumor uptake could be visualized and quantified with 89 Zr-fresolimumab PET. 13 Therefore, the aim of this study was to visualize and quantify fresolimumab uptake in recurrent high-grade glioma using 89 Zr-fresolimumab PET. In addition, we evaluated the effect of treatment with fresolimumab in patients with recurrent high-grade glioma.
MAterIAl And Methods
Patients
Adult patients who had recurrent glioma with one or more contrast-enhancing lesions of at least 20 mm on MR imaging were eligible. The main additional inclusion criteria were a 
Imaging
Conjugation and radio labeling of fresolimumab were performed under good manufacturing conditions as previously described. 13 Before the start of treatment with fresolimumab, patients were injected with 37 MBq (5 mg) of Zr-fresolimumab uptake was quantified using AMIDE Medical
Image Data Examiner software, version 0.9.2 (Stanford University), to calculate the standardized uptake value (SUV). 14 The SUVmax of the tumor lesions and the SUVmean of normal organs, including blood (measured in the sinus confluens and the iliac artery), were calculated. Followup brain MR imaging (1.5 T using T1-, T2-, and contrast-enhanced 3D T1-weighted gradientecho sequences) was performed after every 3 treatment cycles (every 9 weeks) or as clinically indicated. MR imaging data for this study were assessed by a neuroradiologist using the criteria of Macdonald et al. for tumor response evaluation.
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Plasma pharmacokinetics and biomarkers
Heparin plasma samples for 89 Zr-fresolimumab pharmacokinetics were collected from patients 1 h after injection and at the time of PET scanning. Plasma samples were counted in a gamma counter, and the tracer concentration in plasma was calculated using a calibration graph. Before the start of fresolimumab treatment, citrate plasma samples were collected. Blood samples were drawn without a tourniquet when possible, immediately placed on ice, and centrifuged at 2,500g for 30 min at 4˚C with the brake turned off. Plasma samples were stored at -70˚C. In these samples, total TGF-β1 was analyzed using a human TGF-β1 immunoassay (Quantikine;
R&D Systems).
An analysis of p-SMAD2 as a readout of TGF-β signaling was performed in archival paraffin- at 4˚C overnight was followed by incubation with goat anti-rabbit antibody conjugated to peroxidase (Dako) and subsequently with rabbit anti-goat antibody conjugated to peroxidase (Dako). Staining was visualized by 3,39-diaminobenzidine, and sections were counterstained with hematoxylin and mounted. As a negative control, primary antibody was omitted and incubations were performed as described previously.
statistical analysis
In the protocol, 2 stopping rules were defined. The study would be terminated after the inclusion No adverse events were related to tracer injection. In 12 patients, 69 nonhematologic adverse events, mostly grade 1 or 2 and mostly related to progression of the disease, were observed during the study. Thirteen hematologic grade 1 adverse events were registered. The most common adverse events were neurologic deterioration, headache, skin disorders, nausea, and fatigue (Table 2) . Adverse events that were considered as possibly related to fresolimumab were acneiform rash (grade 1, 1 patient), dry skin (grade 1, 1 patient), fatigue (grade 2, 2 patients), thrombocytopenia (grade 1, 1 patient), and epistaxis (grade 1, 1 patient). Four serious adverse events were recorded, of which 3 were neurologic worsening related to progressive disease and 79 1 was pain related to an osteoporotic vertebra fracture, all of which were assessed as unrelated to fresolimumab.
In 4 patients, no MR imaging after treatment was performed because of clinical deterioration.
In 2 patients, suspected dispersed hemorrhagic spots were seen in the tumor on MR imaging after treatment. A relationship with fresolimumab could not be excluded, although one of these patients also had a second course of radiotherapy before entrance into the study. Zr-fresolimumab uptake. Most tumor lesions that did not show uptake were small (< 10 mm on MR imaging). In 3 patients, no uptake was seen in larger gadolinium-enhanced lesions of Tumor/blood ratio 13, 18 , and 12 mm. The latter 2 lesions were found in previously irradiated areas, and one of these was not visible on the follow-up MR imaging (Fig. 2) . In all 4 patients who underwent a PET scan on both day 2 and day 4 after injection, the tumor-to-blood ratio (measured in the sinus confluens) increased from day 2 to day 4 after injection (Fig. 2) . There was no correlation between tumor uptake and PFS or overall survival.
Plasma pharmacokinetics and biomarkers
The mean plasma concentrations of (Fig. 3) . Staining in primary tumor tissue with p-SMAD2 was positive for all tumors but also for normal brain tissue (Fig. 4) . tumors. 16 The maximum concentration per dose of 89 Zr-fresolimumab 1 h after injection of 0.37 mg/mL/mg is comparable to the pharmacokinetic results of an earlier study with fresolimumab. 17 This indicates that the radiolabeled antibody has a maximum concentration similar to that found for fresolimumab in other studies. Three contrast-enhancing lesions larger than 10 mm did not take up 89
Zr-fresolimumab. Two were found in previously irradiated areas, and one of these disappeared on follow-up MR imaging. These lesions are suspected to represent radionecrosis instead of viable tumor tissue, which might be the reason for the lack of TGF-β and uptake of 89 Zr-fresolimumab. In all patients who underwent a whole-body PET scan on both day 2 and day 4 after injection, the tumor-to-blood ratio increased. This increase in ratio supports the notion of tumor-specific uptake. This pattern of tumor accumulation and increasing tumorto-blood ratios over time was also seen in our preclinical study with Zr-trastuzumab in patients with metastatic breast cancer. 13, 18 Taken together, these findings suggest that 89
Zr-fresolimumab uptake not only was a reflection of antibody leakage due to a damaged blood-brain barrier but was tumor-specific and TGF-β-driven.
In earlier studies, the uptake of gemcitabine and GRN1005 in patients with recurrent glioma was shown by analyzing tumor tissue obtained during surgery. 19, 20 However, performing tumor biopsies is often not feasible in this patient group, and tumor characteristics may change over time. PET scanning can be a noninvasive alternative for exploring potential targets that may be influenced by drugs and showing tumor penetration of drugs.
Treatment with fresolimumab was generally well tolerated, without infusion-related reactions. Most adverse events were grade 1 or grade 2 and related to progression of the disease. Unfortunately, no clinical benefit was observed in this small and often extensively pretreated patient group in which only one dose of fresolimumab was tested. Possible effects of this treatment in higher doses can therefore not be excluded. The median PFS was 61 d, which is comparable to the PFS of the physician-choice chemotherapy arm in recurrent GBM in a recently conducted randomized phase 3 trial. 21 In all archival tumor samples, p-SMAD2 was positive, indicating that the TGF-β pathway was active in the tumors. In gliomas, multiple signaling pathways are activated, and inhibition of just one pathway might be insufficient for a response. 22 Recently, other clinical studies using TGF-β inhibition in glioma patients have been published. Traberdersen is an antisense oligodeoxynucleotide that inhibits TGF-β2. In a randomized grade 2B study, traberdersen was administered intratumorally by convection-enhanced delivery and compared with standard chemotherapy in patients with recurrent or refractory high-grade glioma. Sixmonth tumor control rates did not significantly differ among the entire study population (anaplastic astrocytoma and GBM). A prespecified anaplastic astrocytoma subgroup analysis showed a significant benefit regarding the 14-months tumor control rate for traberdersen vs.
Chapter 4 84 4 chemotherapy. 23 A phase 1 study with LY2157299 (a TGF-β1 receptor kinase inhibitor) showed confirmed responses in treatment-refractory gliomas in 3 of 28 patients. 24 Therefore, TGF-β remains a potential interesting target in glioma patients, and more combination studies are welcomed.
conclusion
This study proved that an antibody against TGF-β reaches recurrent high-grade gliomas.
Although no treatment benefit was seen, this finding could be exploited for further development of recurrent high-grade glioma treatment with antibodies or antibody-drug conjugates.
disclosure
The costs of publication of this article were defrayed in part by the payment of page charges.
Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by Genzyme (Sanofi-Aventis Oncology), including a grant for PET scans that was made available to the UMCG. 
Funding
This work was supported by Genzyme (Sanofi-Aventis Oncology). Grant of Genzyme (SanofiAventis Oncology) for PET scans to EGE de Vries was made available to the UMCG.
85
